Henry Schein (HSIC) Announces Completion of $250 Million Investment by KKR

Henry Schein, Inc. (NASDAQ:HSIC) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The company announced the completion of a $250 million strategic investment by funds affiliated with KKR, which is a leading global investment firm. Furthermore, William K. “Dan” Daniel has officially joined Henry Schein, Inc. (NASDAQ:HSIC)’s Board of Directors as an independent director. He joined Max Lin, who became a member of the company’s Board on May 2, 2025. As per Henry Schein, Inc. (NASDAQ:HSIC)’s Chief Executive Officer, deep experience of these appointments in health care, operations, and strategic growth is expected to be invaluable, with the company executing on its BOLD+1 strategy and creating long-term value.

Henry Schein, Inc. (NASDAQ:HSIC) continues to advance its BOLD+1 Strategic Plan, which was refreshed for 2025 to 2027, with the team focused towards growing distribution business via enhanced operational efficiency and improved customer experience, growing the dental and medical specialty businesses and corporate brand products as well as further developing the digital footprint and digital solutions. The company remains committed to its long-term financial goal of high single-digit to low double-digit earnings growth through successfully executing against the strategy.

While we acknowledge the potential of HSIC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.